Although the efficacy of statins in women with coronary artery disease (CAD) is established and similar to that noted in men, their benefit in preventing events in asymptomatic women is controversial. A meta-analysis concluded that statins reduce CAD in men without prior disease but that in women the reduction was not statistically significant.1 However, this analysis did not include the largest primary prevention trial, the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER).2 After analysing sex-specific outcomes from JUPITER and including them in an updated meta-analysis, Mora and colleagues conclude that statins are effective for primary prevention in selected women.